

By

Kristina L. Konstas

(Signature of person mailing)

Kristina L. Konstas

(Typed or printed name of person)

RECEIVED

APR 15 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: YUHPYNG L. CHEN :

Examiner: T. Truong

APPLICATION NO.: 09/761,995 :

Group Art Unit: 1624

FILING DATE: January 17, 2001 :

TITLE: CORTICOTROPIN RELEASING
FACTOR ANTAGONISTS :

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patent
Washington, D.C. 20231

Sir:

Communication in Response to February 26, 2002 Office Action

This Communication is in response to the Office Action issued February 26, 2002 issued by the United States Patent and Trademark Office in connection with the above-identified patent application. A response to the February 26, 2002 Office Action was indicated as being due one month from the mailing date thereof, i.e. by March 26, 2002. Accordingly, this Communication is being timely filed.

In the February 26, 2002 Office Action the Examiner set forth a requirement to restrict the claims of the subject application, claims 1-22, to one of Groups I-VI. In this regard, the Examiner stated that each of the Groups I-VI is drawn to a ring system that is distinct and patentable over the ring systems of the other Groups. The Examiner stated that prior art that renders obvious one Group would not do so to another.

In response, applicant elects to prosecute in this application the subject matter of Group I, compounds, compositions, and methods of treatment comprising compounds of formula I wherein A is CR₇. The election is made without traverse. Claims 1-22 of the subject application are directed, in whole or in part, to the elected Group I.

It is noted that Group VI said forth in the February 26, 2002 Office Action appears identical to the elected Group I. Perhaps the Examiner meant for Group VI to be directed to compounds, compositions, and methods of treatment using compounds of formula III wherein A is CR₇. Clarification is requested.

No fee, is believed necessary for filing this Communication. However, if any fee is found necessary for filing this Communication, authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

Respectfully submitted,

Date:

March 26, 2002

Kristina L. Konstas

Kristina L. Konstas

Attorney for Applicant(s)

Reg. No. 37,864

Pfizer, Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5612
(212) 733-6380